Home

Correction: Acadia Pharmaceuticals story

By Associated Press
June 17, 2008 | Comments (0)

Recs

0

In a June 16 story about Acadia Pharmaceuticals, The Associated Press reported erroneously that pimavanserin is in mid-stage development as an add-on schizophrenia drug. It has completed mid-stage testing. The drug is also in late-stage development for Parkinson's disease psychosis.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

DocumentId: 666555, ~/articles/articlehandler.aspx, 12/2/2008 2:44:44 AM,

Sign up for FREE Motley Fool site access to keep reading:

“Correction: Acadia Pharmaceuticals story”

Signing up allows you to comment on articles and on the discussion boards.

It's completely FREE and will take only 10 seconds.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.